Navigation Links
American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
Date:4/6/2012

NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) (the "Company") today announced that the New York Stock Exchange (the "NYSE") has notified the Company that it is not in compliance with NYSE rules due to the Company's failure to timely file its Annual Report on Form 10-K with the Securities and Exchange Commission.

Under NYSE rules, when a Company does not comply with annual report filing requirements, the NYSE allows a company an additional six months to file its annual report in order to regain compliance.  In the case of the Company, the annual report would be due on or before October 29, 2012.  If the Company fails to file its annual report within that time period, the NYSE may, in its sole discretion, allow the Company's securities to remain listed for up to an additional six months or may, in its sole discretion, commence suspension and delisting procedures. 

As previously announced, during the performance of the annual audit of the Company's financial statements for the fiscal year 2011, the Company's auditors, Ernst & Young Hua Ming's (E&Y), noted certain inconsistencies.  As a result, the Audit Committee has commenced an independent investigation into the matters identified by E&Y.  Although the Company cannot know at this time how long the investigation will take, the Company will endeavor to file the Form 10-K as soon as possible upon the completion of the investigation.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products. 

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:


American Oriental Bioengineering, Inc.

Hong Zhu

(646) 367-1765

 

 


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
2. American Association for Homecare Applauds Efforts to Eliminate Fraud in Medicare
3. Medicare Bidding Program Endangers Patients, Costs Jobs in Pittsburgh, says American Association for Homecare
4. Endo Announces Departure of American Medical Systems President
5. American Foundation for the Blind Announces 2012 Access Award Winners
6. Quest International Donates $5000 to the American Cancer Society
7. Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder
8. Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight
9. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
10. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
11. The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Corp. (NYSE: NVRO), a global medical device company that is ... today reported financial results for the three months and full ... & Highlights: Achieved revenue of $228.5 million ... reported, over the prior year U.S. revenue of ... prior year International revenue of $55.2 million ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Oesophageal Cancer ... What are the key drugs marketed for Oesophageal ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
Breaking Medicine Technology:
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... her Smiling Patriot program today with a new Indiegogo campaign . ... care to homeless veterans in the Los Angeles area, either as a participating patient ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the ... once again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping ... episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish ...
(Date:2/22/2017)... ... February 22, 2017 , ... A cylindrical “pipeline” used for ... to reach ones, according to the results of a clinical trial announced Wednesday. ... by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and Lyerly ...
Breaking Medicine News(10 mins):